SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-060919
Filing Date
2021-12-22
Accepted
2021-12-22 08:30:23
Documents
14
Period of Report
2021-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-8k_20211222.htm   iXBRL 8-K 46960
2 EX-10.1 achv-ex101_44.htm EX-10.1 670226
3 EX-10.2 achv-ex102_9.htm EX-10.2 161070
  Complete submission text file 0001564590-21-060919.txt   1167475

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA achv-20211222.xsd EX-101.SCH 5713
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20211222_lab.xml EX-101.LAB 20049
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20211222_pre.xml EX-101.PRE 11947
8 EXTRACTED XBRL INSTANCE DOCUMENT achv-8k_20211222_htm.xml XML 3674
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 211511056
SIC: 2835 In Vitro & In Vivo Diagnostic Substances